Abeona Therapeutics Inc

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing gene and cell therapies for rare genetic diseases. The company was founded in 1974 and is headquartered in New York City. Abeona's pipeline includes several products in various stages of development, including gene therapies for Sanfilippo syndrome, Batten disease, and Fanconi anemia. The company's lead product candidate is EB-101, a gene therapy for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic disorder that causes severe skin blistering. Abeona is also developing ABO-102, a gene therapy for Sanfilippo syndrome type A, which is currently in Phase 3 clinical trials. The company has partnerships with several academic institutions and biotechnology companies to advance its research and development efforts.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.